BACKGROUND: In patients with Alzheimer's disease (AD), the relationship between cognitive and functional progression is not fully understood; however, functional decline has been postulated to follow cognitive decline. OBJECTIVE: To assess the relationship between cognitive and functional treatment effects in mild AD dementia patients. METHODS: Data of patients with mild AD were pooled from two multicenter, double-blind, Phase 3 studies. Patients were randomized to infusions of 400-mg solanezumab (n = 654), or placebo (n = 660) every 4 weeks for 18 months. Cognitive and functional outcome measures were assessed using the AD Assessment Scale-Cognitive subscale (ADAS-Cog) and the AD Cooperative Study-Activities of Daily Living (ADCS-ADL), respectively. Analyses included comparisons among normalized scales, correlations between outcome measures, and path analyses to model the relationship of treatment effect on cognition and function. RESULTS:Normalized ADAS-Cog and ADCS-ADL scales showed cognitive impairment was more evident than functional impairment in mild AD. The correlation between cognition and function increased over time. Path analyses demonstrated that 87% of the treatment effect on function was driven by the treatment effect on cognition, with the remaining 13% due to direct treatment effect. CONCLUSION: Findings from this study are consistent with the hypothesis that functional impairment is primarily driven by and follows cognitive decline in mild AD dementia. The cognitive treatment effect appeared to explain the majority of the functional treatment effect. It is possible that a cognitive treatment effect may be considered as a leading indicator for functional outcomes in an 18-month clinical trial for milder stages of AD.
RCT Entities:
BACKGROUND: In patients with Alzheimer's disease (AD), the relationship between cognitive and functional progression is not fully understood; however, functional decline has been postulated to follow cognitive decline. OBJECTIVE: To assess the relationship between cognitive and functional treatment effects in mild AD dementiapatients. METHODS: Data of patients with mild AD were pooled from two multicenter, double-blind, Phase 3 studies. Patients were randomized to infusions of 400-mg solanezumab (n = 654), or placebo (n = 660) every 4 weeks for 18 months. Cognitive and functional outcome measures were assessed using the AD Assessment Scale-Cognitive subscale (ADAS-Cog) and the AD Cooperative Study-Activities of Daily Living (ADCS-ADL), respectively. Analyses included comparisons among normalized scales, correlations between outcome measures, and path analyses to model the relationship of treatment effect on cognition and function. RESULTS: Normalized ADAS-Cog and ADCS-ADL scales showed cognitive impairment was more evident than functional impairment in mild AD. The correlation between cognition and function increased over time. Path analyses demonstrated that 87% of the treatment effect on function was driven by the treatment effect on cognition, with the remaining 13% due to direct treatment effect. CONCLUSION: Findings from this study are consistent with the hypothesis that functional impairment is primarily driven by and follows cognitive decline in mild AD dementia. The cognitive treatment effect appeared to explain the majority of the functional treatment effect. It is possible that a cognitive treatment effect may be considered as a leading indicator for functional outcomes in an 18-month clinical trial for milder stages of AD.
Entities:
Keywords:
Activities of daily living; Alzheimer's disease; Phase 3; clinical trials; cognition; correlation of data; dementia; solanezumab
Authors: Antonella Caccamo; Caterina Branca; Ignazio S Piras; Eric Ferreira; Matthew J Huentelman; Winnie S Liang; Ben Readhead; Joel T Dudley; Elizabeth E Spangenberg; Kim N Green; Ramona Belfiore; Wendy Winslow; Salvatore Oddo Journal: Nat Neurosci Date: 2017-07-24 Impact factor: 24.884
Authors: Adam P Ingber; Jason Hassenstab; Anne M Fagan; Tammie L S Benzinger; Elizabeth A Grant; David M Holtzman; John C Morris; Catherine M Roe Journal: J Alzheimers Dis Date: 2016 Impact factor: 4.472
Authors: Brittany L Bernard; Lauren E Bracey; Kathleen A Lane; Denisha Y Ferguson; Michael A LaMantia; Sujuan Gao; Douglas K Miller; Christopher M Callahan Journal: Alzheimer Dis Assoc Disord Date: 2016 Apr-Jun Impact factor: 2.703
Authors: Kah Poh Loh; Michelle C Janelsins; Supriya G Mohile; Holly M Holmes; Tina Hsu; Sharon K Inouye; Meghan S Karuturi; Gretchen G Kimmick; Stuart M Lichtman; Allison Magnuson; Mary I Whitehead; Melisa L Wong; Tim A Ahles Journal: J Geriatr Oncol Date: 2016-07-05 Impact factor: 3.599
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Jennifer Salazar; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2016-12-05 Impact factor: 21.566
Authors: B Vellas; R Bateman; K Blennow; G Frisoni; K Johnson; R Katz; J Langbaum; D Marson; R Sperling; A Wessels; S Salloway; R Doody; P Aisen Journal: J Prev Alzheimers Dis Date: 2015-06
Authors: Barbara Resnick; N Jennifer Klinedinst; Laura Yerges-Armstrong; Jay Magaziner; Denise Orwig; Marc C Hochberg; Ann L Gruber-Baldini; Gregory E Hicks; Susan G Dorsey Journal: Pain Manag Nurs Date: 2016-06 Impact factor: 1.929